IOC, AMRN, HYGS, - CRWESelect.com Stock News! InterOil Corporation, Amarin Corporation plc, Hydrogenics Corporation (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) November 25, 2011 -- To view video, and read the full article visit URL http://crweselect.com/27504/stock-alerts/ioc-amrn-hygs-crweselectcom-stock-news-interoil-corporation-amarin-corporation-plc-hydrogenics-corporation-video-included-inside/

InterOil Corporation (NYSE:IOC)

IOC and Pacific LNG Operations Ltd. announced the signing of a Heads of Agreement (HOA) with Gunvor Singapore Pte. Ltd., for the supply of one million tonnes per annum (mtpa) of liquefied natural gas (LNG) from the Gulf LNG Project in Papua New Guinea . The signing occurred in Port Moresby and was witnessed and supported by Prime Minister Peter O'Neill, the Gulf Governor Havila Kavo , and other cabinet Ministers.

IOC is developing a vertically integrated energy business whose primary focus is Papua New Guinea and the surrounding region. InterOil's assets consist of petroleum licenses covering about 3.9 million acres, an oil refinery, and retail and commercial distribution facilities, all located in Papua New Guinea . In addition, InterOil is a shareholder in a joint venture established to construct liquefaction facilities in Papua New Guinea .

For more inormation about IOC please visit http://www.interoil.com

****

Amarin Corporation plc (NASDAQ:AMRN)

AMRN, announced today that its New Drug Application (NDA) for AMR101 has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficiently complete to permit a substantive review.

AMRN is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). Amarin reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>=500 mg/dL]), as reported in November 2010, and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [>=200 and <500mg/dL] with mixed dyslipidemia), as reported in April 2011. Both the MARINE and ANCHOR trials were conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. In September 2011, Amarin submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of AMR101 for treatment of the patient population studied in the MARINE trial. Amarin plans to separately seek approval for the population studied in the ANCHOR trial after its REDUCE-IT cardiovascular outcomes trial is substantially underway. In August 2011, an SPA agreement with the FDA was reached for the REDUCE-IT cardiovascular outcomes study. The Company seeks to have this study substantially underway before the end of 2012.

For more inormation about AMRN please visit http://www.amarincorp.com

****

Hydrogenics Corporation (NASDAQ:HYGS)

HYGS, announced today the award to deliver one HySTAT(TM)60 electrolyser, capable to produce 130kg a day of pure hydrogen. It will be part of a complete electrolysis-based fueling station awarded to Carbagas, a fully owned subsidiary of the Air Liquide group. The electrolyser is expected to be delivered to the city of Brugg in the canton of Aargau, Switzerland at the beginning of 2012.

HYGS is a globally recognized developer and provider of hydrogen generation and fuel cell products and services, serving the growing industrial and clean energy markets of today and tomorrow. Based in Mississauga, Ontario, Canada, Hydrogenics has operations in North America and Europe.

For more inormation about HYGS please visit http://www.hydrogenics.com

To read the full article visit URL http://crweselect.com/27504/stock-alerts/ioc-amrn-hygs-crweselectcom-stock-news-interoil-corporation-amarin-corporation-plc-hydrogenics-corporation-video-included-inside/

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

IOCcrweselect1125
AMRNcrweselect1125
HYGScrweselect1125

Amarin Corporation     AMRN     Gunvor Singapore Pte. Ltd.     Hydrogenics Corporation     HYGS     InterOil Corporation     IOC     Pacific LNG Operations Ltd.